30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Trillium Therapeutics Inc (TRIL)

Track

Stock chart
Ticker: TRIL Exchange: TOR
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Uger Robert
Chief Scientific Officer
1 sale — total 30,152 USD
Planned sale 7 Jun 2021
Value US$1,471,355.50 | Price 73.45 | Shares 8,753
Sale 12 May 2021
Value US$4,624,469.39 | Price 171.95 | Shares 66,157
Sale 11 May 2021
Value US$981,802.99 | Price 9.20 | Shares 106,698
Planned sale 7 Apr 2021
Value US$39,449.72 | Price 10.82 | Shares 3,646
Planned sale 12 Mar 2021
Value US$34,916.49 | Price 11.97 | Shares 2,917
Planned sale 10 Mar 2021
Value US$58,856.96 | Price 11.08 | Shares 5,312
Planned sale 8 Mar 2021
Value US$36,861.06 | Price 10.11 | Shares 3,646
Planned sale 9 Feb 2021
Value US$8,248.42 | Price 14.12 | Shares 584
Planned sale 9 Feb 2021
Value US$7,200.39 | Price 14.17 | Shares 508
Planned sale 8 Feb 2021
Value US$83,021.95 | Price 12.65 | Shares 6,563
Planned sale 8 Feb 2021
Value US$67,196.80 | Price 12.65 | Shares 5,312
Planned sale 14 Jan 2021
Value US$294,278.93 | Price 15.03 | Shares 19,581
Planned sale 13 Jan 2021
Value US$81,507.72 | Price 15.04 | Shares 5,419
Planned sale 11 Jan 2021
Value US$7,725.31 | Price 15.21 | Shares 508
Planned sale 11 Jan 2021
Value US$8,878.67 | Price 15.20 | Shares 584
Planned sale 8 Jan 2021
Value US$45,230.42 | Price 15.51 | Shares 2,917
Planned sale 8 Jan 2021
Value US$88,575.20 | Price 15.82 | Shares 5,600
Planned sale 8 Jan 2021
Value US$134,270.99 | Price 15.79 | Shares 8,505
Planned sale 8 Jan 2021
Value US$40,364.60 | Price 15.50 | Shares 2,604
Planned sale 7 Jan 2021
Value US$39,842.80 | Price 14.71 | Shares 2,708
Planned sale 7 Jan 2021
Value US$53,782.15 | Price 14.75 | Shares 3,646
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2021-06-09 2021-06-07 PlS Planned sale
Uger Robert

Chief Scientific Officer

Officer
8,753 -42.0%
73.45
US$1,471,356 		8,753 -42.0% 73.45 US$1,471,356
2021-05-13 2021-05-12 S Sale
1.5
Skvarka Jan

President and CEO

Executive Director
66,157 -24.0%
171.95
US$4,624,469 		66,157 -24.0% 171.95 US$4,624,469
2021-05-13 2021-05-11 S Sale
1.5
Skvarka Jan

President and CEO

Executive Director
92,512 +1.1%
171.80
US$521,932 		92,512 +1.1% 171.80 US$521,932
2021-04-09 2021-04-07 PlS Planned sale
Uger Robert

Chief Scientific Officer

Officer
3,646 -100.0%
10.82
US$39,450 		3,646 -100.0% 10.82 US$39,450
2021-03-15 2021-03-12 PlS Planned sale
Uger Robert

Chief Scientific Officer

Officer
2,917 -100.0%
11.97
US$34,916 		2,917 -100.0% 11.97 US$34,916
2021-03-12 2021-03-10 PlS Planned sale
Petrova Penka

Chief Development Officer

Officer
5,312 -100.0%
11.08
US$58,857 		5,312 -100.0% 11.08 US$58,857
2021-03-10 2021-03-08 PlS Planned sale
Uger Robert

Chief Scientific Officer

Officer
3,646 -100.0%
10.11
US$36,861 		3,646 -100.0% 10.11 US$36,861
2021-02-10 2021-02-09 PlS Planned sale
Uger Robert

Chief Scientific Officer

Officer
584 -100.0%
14.12
US$8,248 		584 -100.0% 14.12 US$8,248
2021-02-10 2021-02-09 PlS Planned sale
Petrova Penka

Chief Development Officer

Officer
508 -100.0%
14.17
US$7,200 		508 -100.0% 14.17 US$7,200
2021-02-10 2021-02-08 PlS Planned sale
Uger Robert

Chief Scientific Officer

Officer
6,563 -100.0%
12.65
US$83,022 		6,563 -100.0% 12.65 US$83,022
2021-02-10 2021-02-08 PlS Planned sale
Petrova Penka

Chief Development Officer

Officer
5,312 -100.0%
12.65
US$67,197 		5,312 -100.0% 12.65 US$67,197
2021-01-15 2021-01-14 PlS Planned sale
1.5
Skvarka Jan

President and CEO

Executive Director
19,581 -100.0%
15.03
US$294,279 		19,581 -100.0% 15.03 US$294,279
2021-01-15 2021-01-13 PlS Planned sale
1.5
Skvarka Jan

President and CEO

Executive Director
5,419 -100.0%
15.04
US$81,508 		5,419 -100.0% 15.04 US$81,508
2021-01-13 2021-01-11 PlS Planned sale
Petrova Penka

Chief Development Officer

Officer
508 -100.0%
15.21
US$7,725 		508 -100.0% 15.21 US$7,725
2021-01-13 2021-01-11 PlS Planned sale
Uger Robert

Chief Scientific Officer

Officer
584 -100.0%
15.20
US$8,879 		584 -100.0% 15.20 US$8,879
2021-01-12 2021-01-08 PlS Planned sale
Uger Robert

Chief Scientific Officer

Officer
2,917 -100.0%
15.51
US$45,230 		2,917 -100.0% 15.51 US$45,230
2021-01-12 2021-01-08 PlS Planned sale
Uger Robert

Chief Scientific Officer

Officer
5,600 -100.0%
15.82
US$88,575 		5,600 -100.0% 15.82 US$88,575
2021-01-12 2021-01-08 PlS Planned sale
Parsons James T.

Chief Financial Officer

Officer
8,505 -100.0%
15.79
US$134,271 		8,505 -100.0% 15.79 US$134,271
2021-01-12 2021-01-08 PlS Planned sale
Petrova Penka

Chief Development Officer

Officer
2,604 -100.0%
15.50
US$40,365 		2,604 -100.0% 15.50 US$40,365
2021-01-11 2021-01-07 PlS Planned sale
Petrova Penka

Chief Development Officer

Officer
2,708 -100.0%
14.71
US$39,843 		2,708 -100.0% 14.71 US$39,843
2021-01-11 2021-01-07 PlS Planned sale
Uger Robert

Chief Scientific Officer

Officer
3,646 -100.0%
14.75
US$53,782 		3,646 -100.0% 14.75 US$53,782
Explore more

More insider trading research around Trillium Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America